It is estimated that 25-30 million people are impacted by rare diseases which require orphan drug treatment across Europe. These are patients with conditions which impact one or fewer people per 2000, such as Crohn’s disease or neurofibromatosis.
Orphan drugs, synthetic pharmaceuticals intended to treat very rare diseases, are high cost/low demand products. This means they aren’t developed by the pharmaceutical industry on a very large scale.
Almac explains how, through the use of the Hapa BlisterJet printer, they are able to maximize the stock flexibility of their clients’ valuable orphan drug products, meaning they can distribute product more efficiently between different European countries.